Skip to main content

Table 1 Clinical characteristics of nasopharyngeal carcinoma patients

From: Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model

 

IC + CCRT(n = 220)

CCRT + AC (n = 170)

IC + CCRT + AC(n = 339)

P value

Sex

Male

157 (71.4%)

128 (75.3%)

263 (77.6%)

0.251

Female

63 (28.6%)

42 (24.7%)

76 (22.4%)

 

Age group, years

  ≤ 55

164 a (74.5%)

141 a,b (82.9%)

296 b (87.3%)

0.001

  > 55

56 a (25.5%)

29 a,b (17.1%)

43 b (12.7%)

 

Staging

 III

85 a (38.6%)

88 b(51.8%)

135 a (39.8%)

0.033

 IVA

112 a (50.9%)

61 b (35.9%)

162 a (47.8%)

 

 IVB

23 a(10.5%)

21 a(12.4%)

42 a(12.4%)

 

EBV-DNA levels

  ≤ 1500

97 (54.8%)

51 (46.8%)

122 (51.3%)

0.418

  > 1500

80 (45.2%)

58 (53.2%)

116 (48.7%)

 

Smoking

 Yes

91 (45.5%)

61 (37.9%)

137 (42.9%)

0.339

 No

109 (54.5%)

100 (62.1%)

182 (57.1%)

 

Tumor category

 1

22 a (10.0%)

21 a (12.4%)

42 a (12.4%)

0.040

 2

28 a (12.7%)

40 b (23.5%)

46 a (13.6%)

 

 3

54 a (24.5%)

39 a (22.9%)

75 a (22.1%)

 

 4

116 a (52.7%)

70 a (41.2%)

176 a (51.9%)

 

Node category

 0

12 (5.5%)

11 (6.5%)

20 (5.9%)

0.738

 1

54 (24.5%)

43 (25.3%)

66 (19.5%)

 

 2

127 (57.7%)

94 (55.3%)

210 (61.9%)

 

 3

27 (12.3%)

22 (12.9%)

43 (12.7%)

 
  1. The total percentage may not add up to100% due to rounding. The clinical stages were evaluated according to the 7th edition of the American Joint Committee on Cancer TNM staging system. Data were expressed as n (%); P value was calculated by chi-square test. Each subscript letter denotes a subset of treatment categories whose column proportions do not differ significantly from each other at the 0.05 level